中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
22期
114-115
,共2页
丹红注射液%前列地尔%腔隙性脑梗死%临床疗效
丹紅註射液%前列地爾%腔隙性腦梗死%臨床療效
단홍주사액%전렬지이%강극성뇌경사%림상료효
Danhong Injection%alprostadil%lacunar infarction%clinical effect
目的:观察丹红注射液联合前列地尔治疗老年腔隙性脑梗死的临床疗效。方法将116例老年腔隙性脑梗死患者随机分为对照组和治疗组,各58例。两组患者均采用丹红注射液治疗,治疗组患者加用前列地尔,15 d为1个疗程,服用2个疗程后对比两组患者的临床效果。结果治疗组患者的总有效率为93.10%,明显高于对照组的70.70%( P<0.05)。两组患者均未出现不良反应;两组患者的日常生活活动能力量表(ADL)与简易智能量表(MMSE)的评分存在显著差异( P<0.05)。结论丹红注射液联合前列地尔治疗老年腔隙性脑梗死疗效显著,并发症少,安全性较高,值得临床推广。
目的:觀察丹紅註射液聯閤前列地爾治療老年腔隙性腦梗死的臨床療效。方法將116例老年腔隙性腦梗死患者隨機分為對照組和治療組,各58例。兩組患者均採用丹紅註射液治療,治療組患者加用前列地爾,15 d為1箇療程,服用2箇療程後對比兩組患者的臨床效果。結果治療組患者的總有效率為93.10%,明顯高于對照組的70.70%( P<0.05)。兩組患者均未齣現不良反應;兩組患者的日常生活活動能力量錶(ADL)與簡易智能量錶(MMSE)的評分存在顯著差異( P<0.05)。結論丹紅註射液聯閤前列地爾治療老年腔隙性腦梗死療效顯著,併髮癥少,安全性較高,值得臨床推廣。
목적:관찰단홍주사액연합전렬지이치료노년강극성뇌경사적림상료효。방법장116례노년강극성뇌경사환자수궤분위대조조화치료조,각58례。량조환자균채용단홍주사액치료,치료조환자가용전렬지이,15 d위1개료정,복용2개료정후대비량조환자적림상효과。결과치료조환자적총유효솔위93.10%,명현고우대조조적70.70%( P<0.05)。량조환자균미출현불량반응;량조환자적일상생활활동능역량표(ADL)여간역지능량표(MMSE)적평분존재현저차이( P<0.05)。결론단홍주사액연합전렬지이치료노년강극성뇌경사료효현저,병발증소,안전성교고,치득림상추엄。
Objective To observe the clinical effect of Danhong Injection combined with alprostadil in treating senile lacunar infarc-tion. Methods 116 patients with senile lacunar infarction were randomly divided into the control group and the treatment group,58 cases in each group. The two groups were treated by Danhong Injection,while the treatment group was added with alprostadil. 15 d were a course of treatment. The clinical effects after 2 courses of treatment were compared between the two groups. Results The total effec-tive rate was 93. 10% in the treatment group,which was significantly higher than 70. 70% in the control group( P < 0. 05). No adverse reactions occurred during treatment in the two groups. The scores of the activities of daily living(ADL) and the mini mental state ex-amination(MMSE) had significantly differences between the two groups( P < 0. 05). Conclusion Danhong injection combined with al-prostadil in treating senile lacunar infarction has significantly clinical efficacy,little complications and high safety,which is worthy of clinical promotion.